Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Chelsea and Westminster NHS Foundation Trust
With
Open-label, 2 arm, multi-centre, non-inferiority switch study. Sample size: 60 participants Participant population: HIV-1 infected patients on stable and suppressive triple cART. IMP: Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine \- TDF/3TC/DOR) Study setting: Patients will be identified through HIV clinic visits by their direct study medical care team and visits will be captured on a participant-screening log. A Trial Management Team will facilitate the project and liaise with participating sites in study set-up and progress. Dose and Route of Administration: Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks. Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks). Primary Objective To quantify the effect on lipid profile (change from baseline in total fasting cholesterol to Week 24) of switching from suppressive, stable cART containing ABA/3TC or TAF/FTC plus dolutegravir or bictegravir to Delstrigo (TDF/3TC/DOR) in HIV positive patients. Secondary Objectives To investigate the effect of switch on: 1. Body composition changes when measured by Total Body DXA at week 24 and 48 and by waist circumference 2. Change in insulin sensitivity from baseline to week 24 and 48 by HOMA-IR (glucose \& insulin levels) 3. PBMC cholesterol and cholesteryl levels 4. Adipocytokines by assessing adiponectin, leptin 5. Pituitary hormones (TSH, LH, FSH, IGF-1, Testosterone) 6. Estimated cardiovascular risk (QRISK3 and D:A:D equations) 7. Hepatic steatosis and fibrosis by transient elastography-CAP (FibroScan® with the CAP probe) 8. Dietary, Quality of Life (EuroQoL), and Sleep quality (Pittsburgh Sleep Quality Index) Questionnaires 9. Renal safety by uPCR, eGFR Potential Exploratory Objectives Platelet aggregation \& endothelial markers, metabolomics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
